Last reviewed · How we verify
Oral Anticoagulation in Haemodialysis Patients (AVKDIAL)
Guidelines recommend oral anticoagulation with vitamin K antagonists for atrial fibrillation whenever the CHADS2VASC score is superior or equal to 2. As there are no specific guidelines for the hemodialysis patients with atrial fibrillation, the general guidelines apply. However, several retrospective studies suggest that these patients do not benefit from the oral anticoagulation regarding the risk of stroke and may even experience more bleedings and deaths. The aim of this prospective study is to prospectively compare the hemorrhagic and thrombotic risks of oral anticoagulation in comparison with no anticoagulation in hemodialysis patients with atrial fibrillation.
Details
| Lead sponsor | University Hospital, Strasbourg, France |
|---|---|
| Phase | PHASE4 |
| Status | TERMINATED |
| Enrolment | 50 |
| Start date | Wed Jul 12 2017 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Fri Dec 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Kidney Failure, Chronic
Interventions
- No oral anticoagulation
- Oral anticoagulation with vitamin K antagonists
Countries
France